Respiri, APA partner to give 1.1m patients access to wheezo study
Health & Biotech
Health & Biotech
Link copied to
Special Report: Respiri (ASX:RSH) has won over the Australian Patients Association (APA) for its wheezo Experiential Program, a real-world asthma management study designed to support people living with the condition.
The partnership will connect APA’s 1.1 million patients in Australia and 15,000 healthcare practitioners with Respiri and the wheezo study.
The study itself is a real-world investigation into how the smart technology in the wheezo device and app can help asthma patients and their doctors to monitor and log their wheeze, asthma symptoms, medication usage, and importantly, digitise their asthma action plans.
“We’re working with APA to make sure the experiential program is made available to people in their organisation who want to try the technology to help manage their condition in the real world,” Respiri chief and managing director Marjan Mikel told Stockhead.
“Respiri is also partnering with organisations that share our values around delivering positive outcomes for patients, and APA is very aligned with us on this purpose.”
Mikel also said demand for participation in the study, following its launch last month, was extremely high.
APA chief Stephen Mason says as they’re dedicated to championing and protecting the rights and interests of all patients, they are keen to support the wheezo study.
“We want to see wheezo used in the real-world, tested by patients and their doctors, so that we can better understand the role it plays in asthma management and improvements in individual asthma care,” he said.
Mikel says the partnership is a win for both organisations.
“Having patients participate in our real-world study and using our platform, is very valuable and will allow us to evolve the platform to truly meet the needs of asthma patients and extend asthma care beyond the clinic,” he said.
This article was developed in collaboration with Respiri, a Stockhead advertiser at the time of publishing.
This article does not constitute financial product advice. You should consider obtaining independent advice before making any financial decisions.